Search

Anna Berkenblit

age ~52

from Needham, MA

Also known as:
  • Anna D
  • Ann Berkenblit
60 Hoover Rd, Needham, MA 02494

Anna Berkenblit Phones & Addresses

  • 60 Hoover Rd, Needham Heights, MA 02494
  • Needham, MA
  • Brattleboro, VT
  • Stratton, VT
  • Brookline, MA
  • Ann Arbor, MI
  • Schenectady, NY
  • Jamaica Plain, MA
  • Kalamazoo, MI

Work

  • Company:
    Aveo
    Sep 2011 to 2012
  • Address:
    Cambridge, MA
  • Position:
    Head of clinical research

Education

  • School / High School:
    Harvard Medical School
    1994

Languages

English

Awards

Healthgrades Honor Roll

Ranks

  • Certificate:
    Hematology, 2003

Industries

Pharmaceuticals

Specialities

Hematology • Medical Oncology • Oncology

Vehicle Records

  • Anna Berkenblit

    view source
  • Address:
    19 Helen Rd, Needham, MA 02492
  • Phone:
    7815598132
  • VIN:
    JTDKB20U177610329
  • Make:
    TOYOTA
  • Model:
    PRIUS
  • Year:
    2007
Name / Title
Company / Classification
Phones & Addresses
Anna Berkenblit
Anna Berkenblit MD
Internist
330 Brookline Ave, Boston, MA 02215
6176328696

Medicine Doctors

Anna Berkenblit Photo 1

Dr. Anna Berkenblit, Cambridge MA - MD (Doctor of Medicine)

view source
Specialties:
Hematology
Medical Oncology
Oncology
Address:
35 Cambridgepark Dr, Cambridge, MA 02140
6176657796 (Phone)
Certifications:
Hematology, 2003
Internal Medicine, 1999
Medical Oncology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1994
Medical School
Brigham and Women's Hospital
Graduated: 1994
Medical School
Beth Israel Deaconess Med Center
Graduated: 1994
Anna Berkenblit Photo 2

Anna Berkenblit, North Cambridge MA

view source
Specialties:
Internist
Address:
35 Cambridgepark Dr, North Cambridge, MA 02140
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Us Patents

  • Anti-Tumor Activity Of Cci-779 In Papillary Renal Cell Cancer

    view source
  • US Patent:
    20080255177, Oct 16, 2008
  • Filed:
    Apr 8, 2008
  • Appl. No.:
    12/099394
  • Inventors:
    GARY DUKART - Ambler PA,
    James Joseph Gibbons - Westwood NJ,
    Anna Berkenblit - Needham MA,
    Jay Marshall Feingold - Wynnewood PA,
  • Assignee:
    Wyeth - Madison NJ
  • International Classification:
    A61K 31/436
    A61P 35/00
  • US Classification:
    514291
  • Abstract:
    This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.
  • Cut-Point In Pten Protein Expression That Accurately Identifies Tumors And Is Predictive Of Drug Response To A Pan-Erbb Inhibitor

    view source
  • US Patent:
    20120010240, Jan 12, 2012
  • Filed:
    Jan 4, 2011
  • Appl. No.:
    12/984043
  • Inventors:
    Christina Marie Coughlin - Berwyn PA,
    Jay Marshall Feingold - Wynnewood PA,
    Daniel Steven Johnston - Trappe PA,
    Anna Berkenblit - Needham MA,
    Andrew Louis Strahs - Maynard MA,
    Charles Michael Zacharchuk - Westford MA,
  • Assignee:
    Wyeth LLC - Madison NJ
  • International Classification:
    A61K 31/4709
    A61P 35/00
    G01N 1/30
    C40B 30/04
    G01N 33/53
  • US Classification:
    514313, 506 9, 435 74, 435 21
  • Abstract:
    A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.
  • Treatment Regimen Utilizing Neratinib For Breast Cancer

    view source
  • US Patent:
    20120071507, Mar 22, 2012
  • Filed:
    Mar 24, 2010
  • Appl. No.:
    13/256910
  • Inventors:
    Anna Berkenblit - Needham MA,
    Florence Marie Helene Binlich - Ville D'Avray,
    Paul Goss - Wellesley MA,
  • International Classification:
    A61K 31/4709
    A61P 35/00
  • US Classification:
    514313
  • Abstract:
    An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.
  • Phosphatidylinositol-3-Kinase Pathway Biomarkers

    view source
  • US Patent:
    20130189274, Jul 25, 2013
  • Filed:
    Dec 6, 2010
  • Appl. No.:
    13/514556
  • Inventors:
    Anna Berkenblit - Cambridge MA,
    Christina Marie Coughlin - Berwyn PA,
    Jay Marshall Feingold - Livingston NJ,
    Daniel Stephen Johnston - Collegeville PA,
    Andrew Louis Strahs - Maynard MA,
    Charles Michael Zacharchuk - Cambridge MA,
  • International Classification:
    A61K 39/395
    A61K 45/06
    A61K 31/4709
  • US Classification:
    4241451, 435 612, 435 614, 506 9, 514313
  • Abstract:
    Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.

Resumes

Anna Berkenblit Photo 3

Head Of Clinical Research At Aveo

view source
Position:
Head of Clinical Research at AVEO
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Work:
AVEO - Cambridge, MA since Sep 2011
Head of Clinical Research

Pfizer Pharmaceuticals 2009 - 2010
Asset Team Lead

Wyeth Pharmaceuticals 2005 - Nov 2010
Medical Director

Wyeth Jan 2007 - Dec 2009
Medical Director

Wyeth Research Jan 2007 - Dec 2009
Medical Director
Education:
Harvard Medical School 1990 - 1996
Doctor of Medicine (MD)
Yale University 1986 - 1990

Mylife

Anna Berkenblit Photo 4

Anna Berkenblit Schenect...

view source
Locate Anna Berkenblit online with our advanced people search tool. Find all your old friends and colleagues at MyLife.

News

Teva Pharmaceutical Industries Limited (Nyse:teva) Releases Fda Permitted ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Releases FDA Permitted ...

view source
  • ImmunoGen, Inc. (NASDAQ:IMGN) [Trend Analysis] released that the hired of Anna Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer. The previous to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer co
  • Date: Apr 02, 2015
  • Category: Health
  • Source: Google

Get Report for Anna Berkenblit from Needham, MA, age ~52
Control profile